Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compas.

Business Wire • 14 hours ago

Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise

Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the millions of patients who have cycled through multiple antidepressants without relief, the treatment landscape has long been a graveyard of failed promises.

MarketBeat • Feb 20, 2026

Compass Pathways Announces Pricing of $150 Million Public Offering

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999.

Business Wire • Feb 19, 2026

Compass Pathways' depression treatment meets main goal in late‑stage study

Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.

Reuters • Feb 17, 2026

Why Did Compass Pathways Stock Rocket Higher Today?

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome.

The Motley Fool • Feb 17, 2026

COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript

COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript

Seeking Alpha • Feb 17, 2026

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change.

Business Wire • Feb 17, 2026

Compass Pathways Launches Proposed $150.0 Million Public Offering

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 million of American Depositary Shares (“ADSs”), each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase ADSs. All securities are being offered by Compass Pathways. Compass Pathways expects to g.

Business Wire • Feb 17, 2026

Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot

Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot

Seeking Alpha • Feb 17, 2026

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are sc.

Business Wire • Feb 16, 2026